Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy
Aim. To evaluate whether patients with multiple myeloma at various risks can still benefit the same from autologous stem cell transplantation consolidation in the era of novel agents. We retrospectively analyzed 67 consecutive myeloma patients receiving autologous stem cell transplantation after bor...
Main Authors: | Tianmei Zeng, Lili Zhou, Hao Xi, Weijun Fu, Juan Du, Chunyang Zhang, Hua Jiang, Jian Hou |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2015/613045 |
Similar Items
-
Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
by: Simone A. Minnie, et al.
Published: (2021-03-01) -
UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-01-01) -
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
by: Patrizia Tosi
Published: (2014-07-01) -
UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
by: Patrizia Tosi, et al.
Published: (2012-11-01) -
A simplified method for autologous stem cell transplantation in multiple myeloma
by: Mohamed-Amine Bekadja, et al.
Published: (2012-01-01)